Welcome to our dedicated page for LIVEWORLD news (Ticker: LVWD), a resource for investors and traders seeking the latest updates and insights on LIVEWORLD stock.
LiveWorld Inc. (LVWD) is a leading social content marketing company specializing in moderation, insight, and engagement solutions. We are a trusted partner to some of the world’s largest brands, including top companies in retail, consumer packaged goods (CPG), pharmaceuticals, and financial/travel services.
Our mission is to revolutionize the management of user-generated content (UGC) through innovative proprietary technology and cutting-edge services. By integrating closely with client marketing and customer support teams, LiveWorld scales the human review of UGC to enhance brand engagement in social media.
LiveWorld offers a unique approach that includes the review, management, and analysis of user content. Our services provide 24/7 brand protection through constant moderation and interaction across various social channels, applications, and websites. This
LiveWorld, Inc. (OTC Markets: LVWD) and Sermo have released findings from a survey of 317 US physicians across ten therapeutic categories, confirming the significant influence of Key Opinion Leaders (KOLs) and Digital Opinion Leaders (DOLs) on Healthcare Providers' (HCPs) prescribing behavior. Key findings include:
- 60% of HCPs changed perceptions of medications based on influencer social media content
- 50% changed prescriptions due to influencer content
- 69% engage with influencer content daily
The survey highlights preferences for platforms like Sermo, Instagram, and LinkedIn, with content types such as Q&A sessions and case studies being most engaging. Credibility factors for influencers include credentials, peer endorsements, and evidence-based content. The study also provides insights into generational and specialty-specific preferences, emphasizing the shift in medical information dissemination in the digital age.
LiveWorld, Inc. (OTC: LVWD) reported its Q2 2024 financial results, showing a decrease in revenues and a net loss from operations. Key highlights include:
- Total revenues of $2.8 million, down 9% year-over-year
- Healthcare revenues of $2.4 million
- Net loss from operations of ($134,000)
- Cash increased by $136,000 to $4.8 million
The company expects flat revenues for 2024 compared to 2023 due to tightened corporate budgets and client program attrition. LiveWorld is investing in new solutions and market segments, aiming for future growth in 2025 and beyond.
LiveWorld (OTC Markets: LVWD) announced its financial results for Q1 2024, reporting total revenues of $2.6 million, a 6% decrease from the same period in 2023. Healthcare revenues accounted for $2.3 million. The company recorded a net loss of $498,000, compared to a net income of $134,000 in Q1 2023. Cash reserves decreased by $320,000 to $4.3 million. The company added pharma executives Helen Chang and Jennifer Sherak to its board and published a business report detailing its growth strategy. Management expects reduced losses and increased revenue in the upcoming quarters.
FAQ
What is the current stock price of LIVEWORLD (LVWD)?
What is the market cap of LIVEWORLD (LVWD)?
